Clinical trials
ctDNA clinical trials
Below are recruiting ctdna clinical trials, each written for real people, not researchers. We’re tracking 189 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06744296Recruiting
ctDNA surveillance for HPV-negative head and neck cancer
This trial uses a blood test to look for tiny bits of tumor DNA after treatment for head and neck cancer. It aims to see if this test can detect any remaining cancer cells early, so you and your doctor can make informed decisions.
Boston, MassachusettsAges 18 years+ - NCT07070648Recruiting
Predicting DLBCL treatment response with ctDNA and PET scans
This trial uses a blood test (ctDNA) and PET scans to predict how well standard first-line treatment works for diffuse large B-cell lymphoma (DLBCL). It aims to find out if these tests can guide better care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07058012RecruitingPhase 2
Testing immunotherapy for ctDNA-positive colorectal cancer after treatment
This trial is for people with colorectal cancer whose ctDNA blood test is still positive after surgery and chemotherapy. It tests two immunotherapy drugs (cemiplimab alone or with fianlimab) to see if they can eliminate the remaining cancer cells and prevent the cancer from coming back.
Gainesville, FloridaAges 18 years+ - NCT06977074RecruitingPhase 2
Personalized chemotherapy for lung cancer based on DNA test
This trial tests if a personalized treatment plan, guided by a blood test for tumor DNA, can improve outcomes for people with untreated, surgically removable lung cancer. It combines chemotherapy with immunotherapy before surgery.
Guangzhou, GuangdongAges 18–75 - NCT07058519RecruitingPhase 2
Personalized osimertinib treatment guided by blood test for EGFR lung cancer
This trial tests a personalized treatment plan for advanced lung cancer with an EGFR mutation. It uses a blood test (ctDNA) to guide treatment with osimertinib (a targeted pill) plus chemotherapy. The goal is to see if adjusting therapy based on the blood test results can help you live longer with fewer side effects.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07062016Recruiting
Studying high-risk endometrial cancer with blood and tissue tests
This trial studies tumor DNA in blood and tissue from people with aggressive endometrial cancer to better understand the disease. You donate samples during surgery and follow-up visits.
Rochester, MinnesotaAges 18 years+ - NCT07052578Recruiting
Aggressive prostate cancer study with HRR blood test
This study looks at men with aggressive, high-volume metastatic prostate cancer that is still sensitive to hormone therapy. It will analyze a blood test for HRR gene mutations (like BRCA) to help understand treatment patterns.
ArkhangelskAges 18 years+ - NCT07054879Recruiting
Using a blood test to guide treatment after pancreatic cancer surgery
This trial is for people who had surgery for pancreatic cancer and are now deciding on maintenance therapy. A special blood test (ctDNA) may help doctors choose the best follow-up treatment to prevent the cancer from coming back.
Nanjing, JiangsuAges 18 years+ - NCT07045571Recruiting
DNA blood test for pancreatic cancer prognosis and treatment
This study tests whether a blood test that looks at DNA changes (ctDNA methylation) can help predict how pancreatic cancer will behave and guide treatment decisions. It includes people with suspected pancreatic cancer who are planning surgery or a biopsy.
Shanghai, Shanghai MunicipalityAges Any age - NCT07021989RecruitingPhase 2
ctDNA-Guided Therapy for Relapsed Hodgkin Lymphoma
This trial uses a blood test (ctDNA) to guide treatment for Hodgkin lymphoma that has come back or not responded to one prior treatment. You would receive a combination of drugs (pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin) to see if it works better.
Davis, CaliforniaAges 18 years+ - NCT07012954RecruitingPhase 1/Phase 2
ctDNA-guided treatment for RAS/BRAF wild-type colorectal cancer
This trial tests a combination of two drugs—cetuximab or bevacizumab plus a chemotherapy pill (trifluridine/tipiracil)—for people with metastatic colorectal cancer that has no RAS or BRAF mutations. It's for patients whose cancer grew after first responding to cetuximab, and who have had other treatments since then.
Guangzhou, GuangdongAges 18–75 - NCT06966440Recruiting
MRD-Guided Chemotherapy After Pancreatic Cancer Surgery
This trial tests whether using a special blood test (MRD) to guide chemotherapy after pancreatic cancer surgery can improve outcomes. It is for people who have had their cancer completely removed and are ready for standard follow-up therapy.
ShanghaiAges 18–75 - NCT04957901Recruiting
Tracking a blood marker in children with lymphoma
This study checks whether measuring a blood test called “circulating tumor DNA” (ctDNA) helps monitor childhood lymphoma during treatment. It’s meant to see if ctDNA tracking can provide useful information alongside standard exams.
GuangzhouAges 1–18 - NCT06958107Recruiting
Liquid biopsy study for sarcoma patients
This study uses a simple blood test (liquid biopsy) to look for tiny pieces of tumor DNA in people with sarcoma. It may help doctors learn more about the disease and guide treatment decisions, whether you are just diagnosed, being treated, or have finished treatment recently.
Charlotte, North CarolinaAges Any age - NCT06954805RecruitingPhase 2
Study of ctDNA in PTLD after transplant
This trial looks at a blood test (ctDNA) to track post-transplant lymphoproliferative disorder (PTLD). It tests how well ctDNA measures treatment response and may help guide future care.
Stanford, CaliforniaAges 15 years+ - NCT06951646RecruitingPhase 2
Personalized treatment for advanced lung cancer with long response to first-line therapy
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
ChangshaAges 18–75 - NCT06550427Recruiting
Lymphoma treatment response monitoring with genetic testing
This trial is testing a new way to monitor how well your lymphoma treatment is working. It uses a blood test to look for genetic changes in cancer cells, which may help doctors make better treatment decisions.
TaipeiAges 18 years+ - NCT06929910Recruiting
K4Care test study for metastatic cancer patients
This study tests how well the K4Care blood test can monitor treatment in people with advanced solid tumors like lung, colorectal, breast, or stomach cancer that has spread. Researchers want to see if tracking tumor DNA in the blood helps guide therapy.
Ho Chi Minh City, Hồ Chí MinhAges Any age - NCT06917573RecruitingPhase 2
Cemiplimab for advanced lung cancer with high PD-L1
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
Alicante, AlicanteAges 18 years+ - NCT06893133Recruiting
DNA testing after gastric cancer surgery
This study checks if a blood test can find leftover cancer DNA after stomach cancer surgery. It helps doctors know if more treatment is needed.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06885879Recruiting
Studying ctDNA changes after radiation for liver cancer
This trial studies how radiation therapy (SBRT) affects a DNA fragment in the blood called ctDNA in people with liver cancer. By tracking ctDNA changes, doctors hope to better understand how well the treatment is working and possibly predict outcomes earlier.
Hong KongAges 18 years+ - NCT06875609Recruiting
ctDNA test for skin cancer patients
This trial studies a blood test (ctDNA) in people with a type of skin cancer called cutaneous squamous cell carcinoma. It aims to see if the test can help track the cancer and guide treatment decisions.
Boston, MassachusettsAges 18 years+ - NCT06287749Recruiting
Liquid biopsy for monitoring pancreatic cancer after surgery
This trial is testing a blood test (liquid biopsy) to look for tiny traces of cancer DNA after surgery for pancreatic cancer. It may help doctors understand if the cancer is likely to come back.
Montpellier, HéraultAges 18 years+ - NCT06828991RecruitingPhase 2
Mosunetuzumab for older DLBCL patients with residual ctDNA
This trial tests whether adding a targeted immunotherapy drug called mosunetuzumab after standard chemotherapy can help older adults with DLBCL who still have tiny traces of cancer DNA in their blood. If you qualify, the goal is to reduce the chance of the cancer coming back.
Rochester, New YorkAges 70 years+
Hear when a new ctDNA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ctdna?
- Yes. Clin2 currently lists 189 recruiting ctdna studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ctdna trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ctdna trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.